Rundong Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rundong Jiang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Johann E. Gudjonsson
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
8 shared publications Rachael Bogle
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
7 shared publications- Allison C. Billi
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
5 shared publications Jennifer Fox
Department of Dermatology, University of Michigan Medical School, Ann Arbor, USA
5 shared publicationsLam C. Tsoi
Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA
5 shared publications- J. Michelle Kahlenberg
Department of Dermatology, University of Michigan, Ann Arbor, MI, USA
4 shared publications
Latest Publications
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
TWEAK signaling drives the transition from psoriasis to atopic dermatitis–like inflammation in paradoxical eczema
Targeted biologics have transformed the treatment of inflammatory skin diseases such as plaque psoriasis. However, some patients with psoriasis paradoxically develop eczematous skin reactions after therapy targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), or IL-23. Although paradoxical eczema (PE) resembles atopic dermatitis (AD) clinically and histologically, the molecular mechanisms that drive its development remain poorly understood. Here, we generated high-resolution cellular and spatial maps of human skin using single-cell RNA sequencing, spatial transcriptomics, immunohistochemistry, and in vitro assays, profiling lesional biopsies from patients with PE ( n = 8 donors), alongside healthy control, psoriasis, and AD skin ( n = 4 donors per group). In PE, we identified distinct transcriptional changes characterized by myeloid and T cell expansion and an altered keratinocyte phenotype shaped by TNF-like weak inducer of apoptosis (TWEAK; encoded by TNFSF12 ) signaling through its receptor TNFRSF12A , confirmed at the protein level by immunohistochemistry. To define the underlying mechanism, we stimulated immortalized (N-TERT) and primary human keratinocytes and found that TWEAK acted together with IL-13 to drive a T helper 2– and type I interferon–polarized epithelial program that partially recapitulated the keratinocyte signature of PE lesions. We validated key target genes by quantitative polymerase chain reaction in primary keratinocytes. In THP-1 cells and primary human CD14 + monocytes, anti-TNF treatment induced TWEAK expression, suggesting a compensatory inflammatory circuit. Together, these findings identify the TWEAK–IL-13 axis as a key driver of PE and suggest how cytokine blockade may reshape cutaneous immune responses.
- 4 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (874)
TWEAK signaling drives the transition from psoriasis to atopic dermatitis–like inflammation in paradoxical eczema
Targeted biologics have transformed the treatment of inflammatory skin diseases such as plaque psoriasis. However, some patients with psoriasis paradoxically develop eczematous skin reactions after therapy targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), or IL-23. Although paradoxical eczema (PE) resembles atopic dermatitis (AD) clinically and histologically, the molecular mechanisms that drive its development remain poorly understood. Here, we generated high-resolution cellular and spatial maps of human skin using single-cell RNA sequencing, spatial transcriptomics, immunohistochemistry, and in vitro assays, profiling lesional biopsies from patients with PE ( n = 8 donors), alongside healthy control, psoriasis, and AD skin ( n = 4 donors per group). In PE, we identified distinct transcriptional changes characterized by myeloid and T cell expansion and an altered keratinocyte phenotype shaped by TNF-like weak inducer of apoptosis (TWEAK; encoded by TNFSF12 ) signaling through its receptor TNFRSF12A , confirmed at the protein level by immunohistochemistry. To define the underlying mechanism, we stimulated immortalized (N-TERT) and primary human keratinocytes and found that TWEAK acted together with IL-13 to drive a T helper 2– and type I interferon–polarized epithelial program that partially recapitulated the keratinocyte signature of PE lesions. We validated key target genes by quantitative polymerase chain reaction in primary keratinocytes. In THP-1 cells and primary human CD14 + monocytes, anti-TNF treatment induced TWEAK expression, suggesting a compensatory inflammatory circuit. Together, these findings identify the TWEAK–IL-13 axis as a key driver of PE and suggest how cytokine blockade may reshape cutaneous immune responses.
- Open Access
- 14 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8633
Single-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with heterogeneous and poorly understood mechanisms. We perform single-cell RNA sequencing of lesional (LAD) and non-lesional (NAD) skin from 42 AD patients and 23 healthy controls (HC). Keratinocytes (KCs) are the predominant disease-relevant cell type. In healthy skin, KC differentiation follows a linear trajectory from basal KCs through seven differentiated stages to terminal keratinized cells. In LAD, this process is disrupted, showing a reversed terminal transition mainly driven by DK7 cells. APOD, LYZ and SERPINB4 emerge as LAD-specific regulators linked to IL-13/IL-22 responses, ER stress and oxidative damage. Mitochondrial and ER dysfunction are specifically enriched in LAD DK6 cells, indicating a key pathogenic compartment. Spatial transcriptomics and cell-cell interaction analysis further identify LAD-specific TWEAK signaling from IL-13+ Th2/cycling T cells to Fn14+ basal/differentiated KCs. Here, we reveal disrupted KC differentiation and immune signaling circuits in AD, highlighting potential therapeutic targets.
- 14 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8633
Open AccessSingle-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with heterogeneous and poorly understood mechanisms. We perform single-cell RNA sequencing of lesional (LAD) and non-lesional (NAD) skin from 42 AD patients and 23 healthy controls (HC). Keratinocytes (KCs) are the predominant disease-relevant cell type. In healthy skin, KC differentiation follows a linear trajectory from basal KCs through seven differentiated stages to terminal keratinized cells. In LAD, this process is disrupted, showing a reversed terminal transition mainly driven by DK7 cells. APOD, LYZ and SERPINB4 emerge as LAD-specific regulators linked to IL-13/IL-22 responses, ER stress and oxidative damage. Mitochondrial and ER dysfunction are specifically enriched in LAD DK6 cells, indicating a key pathogenic compartment. Spatial transcriptomics and cell-cell interaction analysis further identify LAD-specific TWEAK signaling from IL-13+ Th2/cycling T cells to Fn14+ basal/differentiated KCs. Here, we reveal disrupted KC differentiation and immune signaling circuits in AD, highlighting potential therapeutic targets.
- Top Cited Papers
A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit
- Open Access
TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Lichen Planopilaris (LPP) is a lymphocyte-mediated scarring alopecia characterized by progressive follicular destruction and fibrosis. In this clinical trial, patients with biopsy proven LPP were treated with deucravacitinib (an oral inhibitor of tyrosine kinase 2 (TYK2)) 6 mg BID for 24 weeks (NCT-06091956). Bulk and single-cell RNA sequencing was performed on paired pre- and post-treatment scalp biopsies from baseline and week 4. Patients (N=10) demonstrated improvements in PGA (88.9%, p=0.008), LPPAI (−2.3 points, SD 1.1, p=0.002) and Skindex-16 (−21.0 points, SD 22.1, p=0.014) scores at week 24. Bulk transcriptomic analysis of untreated LPP revealed upregulation of type I Interferon (IFN)-stimulated genes and pathways related to inflammation, immune activation, keratinization, and extracellular matrix remodelling, with downregulation of immune and inflammatory pathways following treatment. Single-cell RNA-seq of LPP was characterized by enrichment of CD8+GZMK+ T cells which showed downregulation of T-cell receptor signaling as well as antiviral pathways with treatment. Basal keratinocytes exhibited reduced cytokine and interferon signaling and decreased communication with NK cells following treatment. CCL19+ fibroblasts were prominent in untreated disease was attenuated after treatment, with downregulation of type I IFN signaling. Selective TYK2 inhibition with deucravacitinib effectively suppresses these inflammatory circuits in LPP and represents a promising therapeutic strategy.
Open AccessTYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Lichen Planopilaris (LPP) is a lymphocyte-mediated scarring alopecia characterized by progressive follicular destruction and fibrosis. In this clinical trial, patients with biopsy proven LPP were treated with deucravacitinib (an oral inhibitor of tyrosine kinase 2 (TYK2)) 6 mg BID for 24 weeks (NCT-06091956). Bulk and single-cell RNA sequencing was performed on paired pre- and post-treatment scalp biopsies from baseline and week 4. Patients (N=10) demonstrated improvements in PGA (88.9%, p=0.008), LPPAI (−2.3 points, SD 1.1, p=0.002) and Skindex-16 (−21.0 points, SD 22.1, p=0.014) scores at week 24. Bulk transcriptomic analysis of untreated LPP revealed upregulation of type I Interferon (IFN)-stimulated genes and pathways related to inflammation, immune activation, keratinization, and extracellular matrix remodelling, with downregulation of immune and inflammatory pathways following treatment. Single-cell RNA-seq of LPP was characterized by enrichment of CD8+GZMK+ T cells which showed downregulation of T-cell receptor signaling as well as antiviral pathways with treatment. Basal keratinocytes exhibited reduced cytokine and interferon signaling and decreased communication with NK cells following treatment. CCL19+ fibroblasts were prominent in untreated disease was attenuated after treatment, with downregulation of type I IFN signaling. Selective TYK2 inhibition with deucravacitinib effectively suppresses these inflammatory circuits in LPP and represents a promising therapeutic strategy.
- Open Access
- 14 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus
Lichen planus (LP) is a chronic inflammatory disease of the skin and mucous membranes, marked by T cell infiltration and keratinocyte apoptosis. However, its immune microenvironment remains poorly understood. Using single-cell RNA sequencing, spatial transcriptomics, and proteomics on samples from 28 patients and 18 healthy controls, we identify elevated interferon (IFN) and cytotoxic signatures in CXCL13+CD8+ T cells in both cutaneous and mucosal LP, but not in lichen planopilaris. T cells expressing TNF and IFNG are spatially linked to epithelial cells through ligand-receptor interactions, correlating with inflammation. We identify cDC2A cells as key contributors, proximal to CXCL13+CD8+ T cells, serving as a major source of IL-15. CXCL13+CD8+ T cells express TNFRSF9 (4-1BB), which enhances their cytotoxic responses in the skin. In summary, our data reveal a critical role for cDC2A in driving CXCL13+CD8+ T-epithelial cytotoxicity in cutaneous and mucosal LP through TNFRSF9.
- 14 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSingle-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus
Lichen planus (LP) is a chronic inflammatory disease of the skin and mucous membranes, marked by T cell infiltration and keratinocyte apoptosis. However, its immune microenvironment remains poorly understood. Using single-cell RNA sequencing, spatial transcriptomics, and proteomics on samples from 28 patients and 18 healthy controls, we identify elevated interferon (IFN) and cytotoxic signatures in CXCL13+CD8+ T cells in both cutaneous and mucosal LP, but not in lichen planopilaris. T cells expressing TNF and IFNG are spatially linked to epithelial cells through ligand-receptor interactions, correlating with inflammation. We identify cDC2A cells as key contributors, proximal to CXCL13+CD8+ T cells, serving as a major source of IL-15. CXCL13+CD8+ T cells express TNFRSF9 (4-1BB), which enhances their cytotoxic responses in the skin. In summary, our data reveal a critical role for cDC2A in driving CXCL13+CD8+ T-epithelial cytotoxicity in cutaneous and mucosal LP through TNFRSF9.
- Open Access
- 23 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Dynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis
Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis characterized by epidermal neutrophil infiltration, often presenting as acute, potentially life-threatening flares. However, the characterization of the immune micro-environment in GPP lesions remains largely unknown. Here, we use single-cell RNA profiling to interrogate the transcriptomes of 60,000 single cells from GPP lesional skin (n = 13) and healthy adult skin (n = 4), combined with spatial transcriptomics. We identify a neutrophil subset lacking CASP8 expression but exhibiting elevated levels of inflammatory pathway genes, including RIPK1, NFKB1, IL1B, CXCL1, and CXCL8 in GPP flares, illustrating neutrophil transition from pre-inflammatory to a pro-inflammatory state, and activation of a communication network between IL36G+ keratinocytes and neutrophils in GPP lesions, with TNFSF15 (TL1A) released from neutrophils exaggerating the inflammatory crosstalk. We further demonstrate that fibroblasts and capillary endothelial cells function as central communication hubs in GPP, through dynamic receptor-ligand interactions with several spatially proximate immune cells, including T cells, neutrophils, and macrophages. In this work, we provide an in-depth view of immune cell participation and highlight the role of neutrophil-keratinocyte crosstalk in GPP pathogenesis.
- 23 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDynamic neutrophil-keratinocyte communication network centered on IL-36/TNFSF15 responses characterizes inflammatory responses in generalized pustular psoriasis
Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis characterized by epidermal neutrophil infiltration, often presenting as acute, potentially life-threatening flares. However, the characterization of the immune micro-environment in GPP lesions remains largely unknown. Here, we use single-cell RNA profiling to interrogate the transcriptomes of 60,000 single cells from GPP lesional skin (n = 13) and healthy adult skin (n = 4), combined with spatial transcriptomics. We identify a neutrophil subset lacking CASP8 expression but exhibiting elevated levels of inflammatory pathway genes, including RIPK1, NFKB1, IL1B, CXCL1, and CXCL8 in GPP flares, illustrating neutrophil transition from pre-inflammatory to a pro-inflammatory state, and activation of a communication network between IL36G+ keratinocytes and neutrophils in GPP lesions, with TNFSF15 (TL1A) released from neutrophils exaggerating the inflammatory crosstalk. We further demonstrate that fibroblasts and capillary endothelial cells function as central communication hubs in GPP, through dynamic receptor-ligand interactions with several spatially proximate immune cells, including T cells, neutrophils, and macrophages. In this work, we provide an in-depth view of immune cell participation and highlight the role of neutrophil-keratinocyte crosstalk in GPP pathogenesis.
- Open Access
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
The phase 2 KNOCKOUT (NCT05283135) study evaluates higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-severe plaque psoriasis. Patients received either 300 or 600 mg of risankizumab at Weeks 0, 4, and 16 and were monitored for 100 weeks without further dosing. Efficacy and safety were tracked throughout the study and lesional/non-lesional tissue was evaluated by RNASeq. The primary endpoint was the change in baseline in number and/or function of tissue resident memory T cells (TRM) at week 52. The secondary endpoints were Psoriasis Areas and Severity Index (PASI) 100 at weeks 28, 40, and 52 and safety events over 100 weeks. Nine patients per treatment group completed dosing. At Weeks 28 and 52, PASI 75/90/100 responses were: 94.4%/94.4%/83.3% and 77.8%/61.1%/44.4% of all patients, respectively, with no new safety signals. At Week 52, TRM cell numbers in lesional skin were markedly reduced, with numbers similar to non-lesional TRM numbers at Week 0. High skin clearance rates with higher-than-approved initial dosing of risankizumab with prolonged maintenance of skin clearance, despite the lack of continuous dosing, represent a potential alternative treatment strategy for patients with psoriasis.
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
The phase 2 KNOCKOUT (NCT05283135) study evaluates higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-severe plaque psoriasis. Patients received either 300 or 600 mg of risankizumab at Weeks 0, 4, and 16 and were monitored for 100 weeks without further dosing. Efficacy and safety were tracked throughout the study and lesional/non-lesional tissue was evaluated by RNASeq. The primary endpoint was the change in baseline in number and/or function of tissue resident memory T cells (TRM) at week 52. The secondary endpoints were Psoriasis Areas and Severity Index (PASI) 100 at weeks 28, 40, and 52 and safety events over 100 weeks. Nine patients per treatment group completed dosing. At Weeks 28 and 52, PASI 75/90/100 responses were: 94.4%/94.4%/83.3% and 77.8%/61.1%/44.4% of all patients, respectively, with no new safety signals. At Week 52, TRM cell numbers in lesional skin were markedly reduced, with numbers similar to non-lesional TRM numbers at Week 0. High skin clearance rates with higher-than-approved initial dosing of risankizumab with prolonged maintenance of skin clearance, despite the lack of continuous dosing, represent a potential alternative treatment strategy for patients with psoriasis.
- Open Access
- 7 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (3) , 423-430
Inflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment
Disease states are increasingly recognized as being shaped by spatially organized inflammatory niches, in which immune and non‐immune cells coordinate diverse biological processes, including tissue development, homeostasis and pathology. The activation and composition of specific inflammatory responses, as well as the signalling pathways involved, are highly context‐ and location‐dependent. Recent technological advances—particularly the integration of single‐cell sequencing with spatial profiling—have greatly enhanced our ability to dissect these processes at a molecular level. Such approaches have revealed disease‐specific mechanisms, including IL‐36‐driven feed‐forward amplification in the upper layers of psoriatic epidermis, the complex inflammatory architecture of hidradenitis suppurativa and T‐cell–basal keratinocyte interactions in lichen planus. Continued investigation of inflammatory niches across diseases will deepen our understanding of their pathogenic mechanisms, enable the identification of patient‐specific cellular networks and pave the way for more personalized therapeutic strategies.
- 7 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (3) , 423-430
Open AccessInflammatory niches as spatial drivers of disease mechanisms and targets for personalized treatment
Disease states are increasingly recognized as being shaped by spatially organized inflammatory niches, in which immune and non‐immune cells coordinate diverse biological processes, including tissue development, homeostasis and pathology. The activation and composition of specific inflammatory responses, as well as the signalling pathways involved, are highly context‐ and location‐dependent. Recent technological advances—particularly the integration of single‐cell sequencing with spatial profiling—have greatly enhanced our ability to dissect these processes at a molecular level. Such approaches have revealed disease‐specific mechanisms, including IL‐36‐driven feed‐forward amplification in the upper layers of psoriatic epidermis, the complex inflammatory architecture of hidradenitis suppurativa and T‐cell–basal keratinocyte interactions in lichen planus. Continued investigation of inflammatory niches across diseases will deepen our understanding of their pathogenic mechanisms, enable the identification of patient‐specific cellular networks and pave the way for more personalized therapeutic strategies.
- Open Access
- 22 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-12
Depletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-κB signaling in keratinocyte
Psoriasis is a common and recurrent inflammatory skin disease characterized by inflammatory cells infiltration of the dermis and excessive proliferation, reduced apoptosis, and abnormal keratosis of the epidermis. In this study, we found that G9A, an important methyltransferase that mainly mediates the mono-methylation (me1) and di-methylation (me2) of histone 3 lysine 9 (H3K9), is highly expressed in lesions of patients with psoriasis and imiquimod (IMQ)-induced psoriasis-like mouse model. Previous studies have shown that G9A is involved in the pathogenesis of various tumors by regulating apoptosis, proliferation, differentiation, and invasion. However, the role of G9A in skin inflammatory diseases such as psoriasis remains unclear. Our data so far suggest that topical administration of G9A inhibitor BIX01294 as well as keratinocyte-specific deletion of G9A greatly alleviated IMQ-induced psoriatic alterations in mice for the first time. Mechanistically, the loss function of G9A causes the downregulation of Ectodysplasin A receptor (EDAR), consequently inhibiting the activation of NF-κB pathway, resulting in impaired proliferation and increased apoptosis of keratinocytes, therefore ameliorating the psoriatic dermatitis induced by IMQ. In total, we show that inhibition of G9A improves psoriatic-like dermatitis mainly by regulating cell proliferation and apoptosis rather than inflammatory processes, and that this molecule may be considered as a potential therapeutic target for keratinocyte hyperproliferative diseases such as psoriasis.
- 22 September 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (9) , 1-12
Open AccessDepletion of G9A attenuates imiquimod-induced psoriatic dermatitis via targeting EDAR-NF-κB signaling in keratinocyte
Psoriasis is a common and recurrent inflammatory skin disease characterized by inflammatory cells infiltration of the dermis and excessive proliferation, reduced apoptosis, and abnormal keratosis of the epidermis. In this study, we found that G9A, an important methyltransferase that mainly mediates the mono-methylation (me1) and di-methylation (me2) of histone 3 lysine 9 (H3K9), is highly expressed in lesions of patients with psoriasis and imiquimod (IMQ)-induced psoriasis-like mouse model. Previous studies have shown that G9A is involved in the pathogenesis of various tumors by regulating apoptosis, proliferation, differentiation, and invasion. However, the role of G9A in skin inflammatory diseases such as psoriasis remains unclear. Our data so far suggest that topical administration of G9A inhibitor BIX01294 as well as keratinocyte-specific deletion of G9A greatly alleviated IMQ-induced psoriatic alterations in mice for the first time. Mechanistically, the loss function of G9A causes the downregulation of Ectodysplasin A receptor (EDAR), consequently inhibiting the activation of NF-κB pathway, resulting in impaired proliferation and increased apoptosis of keratinocytes, therefore ameliorating the psoriatic dermatitis induced by IMQ. In total, we show that inhibition of G9A improves psoriatic-like dermatitis mainly by regulating cell proliferation and apoptosis rather than inflammatory processes, and that this molecule may be considered as a potential therapeutic target for keratinocyte hyperproliferative diseases such as psoriasis.